Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00626249 | Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney Function | PHASE1 | COMPLETED | 36 | — | — | Aug 1, 2007 | Oct 1, 2008 | Dec 17, 2013 | 3 | United States |
| Arm | Type | Description |
|---|---|---|
| T Inhalation powder in diabetic subjs w/ normal renal func | EXPERIMENTAL | T inhalation powder in diabetic subjects with normal renal function, Single dose, 30 units |
| T Inhalation powder diabetic subj w/mild or moderate nephrop | EXPERIMENTAL | T Inhalation powder in diabetic subjects w/mild or moderate nephropathy - Single dose, 30 units |
| Name | Type | Description |
|---|---|---|
| Technosphere Inhalation Powder | DRUG | Technosphere Inhalation Powder |
Inclusion Criteria: * Non-smoking males and females, = 18 and = 80 years with a BMI of = 37 kg/m2 * Type 1 or type 2 diabetic * Subjects with mild or moderate DNP and subjects with normal renal function, based on GFR rate and albuminuria * Normal pulmonary function and performance based on PFTs Ex...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | ALN-ANG3, Evinacumab |
| DexCom, Inc. | DXCM | 1 | PHASE3 | Sotagliflozin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | Atrasentan |
| ProKidney Corp. Class A | PROK | 2 | — | Renal Autologous Cell Therapy |